A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)
Status:
Completed
Trial end date:
2021-03-04
Target enrollment:
Participant gender:
Summary
This is a Phase 1b, open-label, multi-center, multiple-dose trial designed to estimate the
maximum tolerated dose (MTD) and select the recommended phase 2 dose (RP2D) of avelumab
(MSB0010718C) in combination with axitinib (AG-013736). Once the MTD of avelumab administered
in combination with axitinib is estimated (dose finding portion), the dose expansion phase
will be opened to further characterize the combination in term of safety profile, anti tumor
activity, pharmacokinetics, pharmacodynamics and biomarker modulation.